Skip to content
Medical Health Aged Care

‘Immune confusion’ leads to severe dengue in children: study

UNSW Sydney 4 mins read
Dengue virus is spread mainly by Aedes aegypti mosquitoes. Photo: Mauro Pimentel/Getty Images.

Researchers have identified early warning signs for severe dengue fever, which could lead to better diagnosis and treatment.   


In a new study published in Nature Immunology, researchers from UNSW Sydney and Stanford University have shown that dengue virus can disrupt the immune system in children, leading to more severe disease. These changes in the immune system, referred to as ‘immune confusion’, could be used to diagnose at-risk patients and targeted with therapeutics.

Most people who are infected with dengue virus have no symptoms, or a fever that quickly passes. However, five per cent of people progress to severe dengue, which can mean organ failure and even death within days of symptoms appearing. The risk is particularly high for children, who experience the most severe reactions to dengue virus.

Until now, there was little understanding of why some patients have mild dengue, while others progress to serious disease.

“This study is about trying to understand what is going wrong,” says co-senior author Dr Fabio Zanini, who leads the Fabilab at UNSW Medicine & Health.

“What is happening in the immune system of these children that don’t respond well to the infection?”


Increasing dengue risk

Dengue virus, which is spread by mosquitoes, infects approximately 400 million people each year. People with dengue fever fill hospitals during the wet season in tropical Africa, Asia and South America, where the disease is endemic.

Currently, dengue virus is not endemic in Australia. However, the main carrier mosquito Aedes aegypti can be found in North Queensland, where small outbreaks have occurred.

“For the time being, dengue virus is a problem that is mostly affecting tropical and subtropical countries. But the mosquitos that spread dengue virus are also present in parts of Australia, especially in the north of the country,” Dr Zanini says.

“Also, the habitat range of these mosquitoes is expanding over time because of climate change.”

Despite decades of research, there is a single licensed dengue vaccine (Dengvaxia® manufactured by Sanofi), with limited uptake due to questions about safety and efficacy. There is also no antiviral treatment to limit a patient’s progression to severe dengue fever.


Multi-disciplinary study

For this study, the researchers focused on children as they are at higher risk of severe dengue. The study participants were 19 Colombian children who presented to health care settings with dengue virus infection in the early stages. Roughly half of this group progressed to severe disease.

Four healthy children who presented for routine checkups or elective procedures were included as a control group.

The researchers analysed blood samples taken from the children on the first day that they presented with dengue. They used a technique called single cell RNA sequencing, which allowed them to study individual immune cells in the blood and how the cells were behaving.

“The question was: if we draw blood samples from patients on day one when they show up at the hospital, and use the most advanced technologies and most sophisticated computational algorithms, can we see early signs of progression to severe dengue?” Dr Zanini says.

Close collaboration was needed between researchers with expertise in immunology and clinical medicine, as well as specialised technical skills to analyse the data. Dr Zanini originally trained as a physicist and obtained a PhD in bioinformatics, now using his expertise in data analytics and computer science in medical research. Co-senior author Professor Shirit Einav from Stanford University is a clinical researcher specialising in infectious diseases.


Immune confusion

In the children that progressed to severe dengue disease, the researchers identified three main changes in the immune cells in their blood.

Firstly, they found that antigen presenting cells were behaving differently. Normally, antigen presenting cells take up dengue virus particles, cut them up into smaller pieces, and show these virus fragments to the rest of the body as a warning of infection.

Secondly, B cells became heavily infected with dengue virus and had impaired ability to produce antibodies, which are one of the main weapons of the immune system to fight infections.

“The third element of the puzzle is that certain cells called natural killer cells, and their companions T cells, seem to be in a strange state of quiescence or exhaustion,” Dr Zanini says.

“We expect them to be virus killing machines. Instead, they transform into couch potatoes that watch the action and wonder about whether they should do something or not.”

This immune confusion means that the child’s immune system doesn’t protect them from the virus how it normally would, leading to severe dengue.


Importance of early warning signs

By understanding what goes wrong early in dengue virus infection, we can design diagnostic tests to identify which patients are at risk of severe disease.

“Current methods to predict which patients will progress to severe dengue are based on clinical parameters that appear late in the disease course,” says co-author Dr Yike Xie, who completed her PhD at UNSW Medicine & Health, now working at the University of Gothenburg and AstraZeneca.

“These methods are not sensitive and specific. Doctors have to keep most symptomatic patients in hospital and monitor their subsequent disease progression, which uses a lot of medical resources and leads to waste.”

The changes in patients’ immune systems could also be targeted with therapeutics to prevent progression to severe dengue. For example, clinicians could prescribe a drug that reactivates natural killer cells and T cells to fight the infection.

Already, the researchers are continuing their work to better understand the link between immune confusion and severe dengue, using single cell RNA sequencing and other advanced analytical techniques.

“This is a great example of how important is to get scientists with different backgrounds to collaborate in a team effort. It is the teamwork that makes the science emerge,” Dr Zanini says.

Key Facts:

- Joint study from UNSW Sydney and Stanford University examined why some children get severe dengue fever and others don't

- Researchers found that dengue virus can confuse the immune system, leading to severe symptoms

- These changes in the immune system could serve as early warning signs or be targeted with therapeutics

Contact details:
Maddie Massy-Westropp
News & Content Coordinator, UNSW Medicine & Health
+61 2 9348 1936


More from this category

  • Environment, Medical Health Aged Care
  • 01/12/2023
  • 10:43
West Australian doctors peak bodies

WA doctors and health professionals call for the government to take urgent action on climate change and end fossil fuel expansion to protect health

On the 1st December, just prior to the COP28 Health Day on the 3rd December, representatives of the medical colleges for general practitioners (GPs), emergency doctors, rural and remote doctors, and surgeons, as well as other doctors and health professionals, gather at 8 am on the steps of Parliament House to call on the WA Government take urgent action on climate change and protect the health of Western Australians. Reiterating calls from medical colleges earlier this year in support of ending fossil fuel expansion and climate action, those gathered today ask the WA government to: End expansion of any new…

  • Medical Health Aged Care
  • 01/12/2023
  • 10:12
Australian Dental Industry Association

ADIA congratulates Senators of the Inquiry into the Provision of and Access to Dental Services in Australia

1 December The Australian Dental Industry Association congratulates the Senators of the Senate Select Committee Inquiry into the Provision of and Access to Dental…

  • Contains:
  • Medical Health Aged Care, Research Development
  • 01/12/2023
  • 09:17

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial. Top-line interim results indicate that Aegros’ COVID-19 hyperimmune provides higher levels of antibodies compared to high-titer convalescent plasma. These results are in line with Aegros’ pre-clinical expectations. CHAT compared Aegros’ COVID-19 hyperimmune to COVID-19 convalescent plasma. The hyperimmune was manufactured using Aegros’ patented Haemafrac® process. A hyperimmune is an intravenous immunoglobulin rich in antibodies that can provide passive immunity for…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.